Lion Point Capital »

Viatris shares owned by Lion Point Capital

Quarter-by-quarter ownership of Viatris (VTRS) shares owned by Lion Point Capital from 13F filings

Historical chart of Lion Point Capital investment in Viatris

Tip: Access up to 7 years of quarterly data

All positions including Viatris held by Lion Point Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Viatris by Lion Point Capital

Quarter filed Position value Share count Share price at filing
2025-12-31 $345k 28k 12.45

More positions owned by Lion Point Capital

Milestone Pharmaceuticals (MIST)
Praxis Precision Medicines I Com New (PRAX)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Fennec Pharmaceuticals (FENC)
Jasper Therapeutics Com New (JSPR)
Benitec Biopharma Com New (BNTC)
Royalty Pharma Shs Class A (RPRX)
Geron Corporation (GERN)
Syndax Pharmaceuticals (SNDX)
Ardelyx (ARDX)
Cue Biopharma (CUE)
Disc Medicine (IRON)
Sarepta Therapeutics (SRPT)
Biohaven (BHVN)
Humacyte (HUMA)

View all positions for Lion Point Capital

Top funds holding Viatris

Vanguard Group
BlackRock
Davis Selected Advisers
State Street Corporation
Dimensional Fund Advisors
Geode Capital Management
Ameriprise Financial
Rubric Capital Management
Invesco
Deerfield Management Company
Bank of New York Mellon
Charles Schwab Investment Management
Citadel Advisors
FMR
Northern Trust

View all funds holding Viatris